Skip to main content
Premium Trial:

Request an Annual Quote

Venter's Genome, RT-PCR Cancer Dx Score High on Time Magazine 'Top 10' Lists

NEW YORK (GenomeWeb News) — Craig Venter’s diploid genome sequence was Time magazine’s second-most important “scientific discovery” in 2007, while an RT-PCR-based breast cancer test made by a Johnson & Johnson subsidiary was the second-most important “medical breakthrough” of the year.
Venter’s genome, the first diploid of a known individual, appeared in the September issue of PLoS Biology. In a press briefing announcing the research, which used Sanger sequencing, Venter said it is “probably the first and last” individual genome to be sequenced by the technology because of the “cost and time involved.”
Venter estimated that the project cost at least $70 million. Still, the “high-quality draft” is not yet finished. To close the gaps and improve the assembly of haplotypes, the scientists are now generating additional data using next-generation sequencing technologies.
The complete Top 10 Scientific Discoveries list can be seen here.
The US Food and Drug Administration in July cleared an RT-PCR assay that detects the spread of breast cancer in the lymph nodes. The test, made by Johnson & Johnson subsidiary Veridex, was No. 2 on Time magazine’s Top 10 list of “medical breakthroughs.”
The intra-operative test, called the GeneSearch breast lymph node assay, uses real time reverse transcriptase PCR on tissue extracted from a sentinel lymph node tissue sample to detect genes indicating that breast cancer has metastasized into the node.
Conducted on Cepheid’s SmartCycler system, the test can generate results in 35 to 40 minutes compared with the two or three days for standard tissue pathology, Veridex said.
The complete Top 10 Medical Breakthroughs can be seen here.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.